NDAORALTABLETPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIEKIRA PAK is a copackaged oral direct-acting antiviral (DAA) combination containing dasabuvir, ombitasvir, paritaprevir, and ritonavir, approved for hepatitis C virus (HCV) treatment. It represents a fixed-dose combination designed to simplify HCV therapy and improve patient adherence. The four-drug regimen targets multiple stages of the HCV replication cycle.
Peak7.1 years to LOE
Product is in peak revenue phase with sustained demand in the HCV market, supporting established commercial teams focused on maintenance and managed care relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIEKIRA PAK offers stability in a mature, high-volume franchise with deep prescriber relationships and established distribution, but limited upside growth potential. Career advancement depends on contributing to pricing defense, market share maintenance, and preparation for post-LOE transition strategies.
Brand ManagerAccount Manager
Worked on VIEKIRA PAK (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.